NCT06034964进行中（未招募）不适用
Retrospective Study of Tislelizumab Combined With Chemotherapy in First-line Treatment of HER2-negative Advanced Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This is a single-center, retrospective clinical study to evaluate the efficacy and safety of tislelizumab combined with first-line chemotherapy in the treatment of HER2-negative advanced gastric cancer.
详细描述
This study aims to include 60 HER-2 negative advanced gastric cancer patients who received first-line treatment with tislelizumab combined with chemotherapy in our hospital from November 1, 2020 to November 1, 2021. Clinicopathological data, blood tests and imaging data of the patients were collected. The primary endpoints evaluated were PFS and OS, and the secondary endpoints were ORR and safety. At the same time, ctDNA and peripheral cytokine status of patients as well as second-generation sequencing of tumor tissues at baseline were collected for the exploration of therapeutic efficacy related biomarkers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with initially unresectable (locally advanced or metastatic) or postoperative recurrence of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma confirmed by histopathology have not received any anti-tumor treatment for advanced gastric cancer in the past;
- •Pathological immunohistochemistry or FISH detection of gastric cancer tissue indicates negative Her-2;
- •Age range from 18 to 70 years old, regardless of gender;
- •The distance between postoperative recurrence and the end of neoadjuvant/adjuvant chemotherapy is more than 6 months;
- •If the patient experiences toxic side effects after receiving new adjuvant/adjuvant treatment, they need to recover from previous treatment toxic side effects to ≤ 1 level; According to the RECIST evaluation criteria, there should be at least one assessable lesion. Expected survival time ≥ 3 months;
- •ECOG score ≤ 2 points;
- •Main organ functions are basically normal, blood count (within 7 days): hemoglobin ≥ 90g/L, white blood cells ≥ 4.0 × 109/L, neutrophils ≥ 2.0 × 109/L, platelet ≥ 100.0 × 109/L. Total bilirubin 1.0 UNL, creatinine 1.0 × UNL, AST/ALT 2.5 UNL. Liver metastasis: ASAT/ALAT 5 UNL;
- •The electrocardiogram/cardiac function tests are basically normal.
排除标准
- •Suffering from undifferentiated gastric cancer or squamous cell carcinoma of the gastroesophageal junction and other pathological types of malignant tumors;
- •Have received anti-tumor treatment for gastric adenocarcinoma or adenocarcinoma at the junction of stomach and esophagus that can not be operated on for the first time or recur after operation, including but not limited to chemotherapy, Targeted therapy, immunotherapy, etc. (except for Thymosin and traditional Chinese medicine treatment);
- •Patients with other primary malignant tumors other than gastric cancer, excluding cured skin Basal-cell carcinoma and cervical Carcinoma in situ;
- •Patients with simple or combined brain metastasis;
- •Has experienced gastrointestinal perforation or fistula within 6 months prior to enrollment;
- •Patients who also suffer from other important organ diseases, including severe heart disease;
- •Complications such as uncontrollable moderate to massive ascites, active gastrointestinal bleeding, gastrointestinal perforation, gastrointestinal obstruction, etc;
- •Patients with chronic diseases such as hypertension, hyperglycemia, and COPD that are difficult to control;
- •Those who require antibiotics for systemic anti infection, active hepatitis, active pulmonary tuberculosis, and other diseases.
结局指标
主要结局
PFS
时间窗: 2 years
Progression-free Survival
OS
时间窗: 3 years
Overall Survival
次要结局
- ORR(2 years)
- DOR(2 years)
- DCR(2 years)
- Safety and Tolerability(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell CarcinomaESCCNCT05547828The First Affiliated Hospital of Xinxiang Medical College20
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20
尚未招募
2 期
Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction AdenocarcinomaGastric/Gastroesophageal Junction AdenocarcinomaNCT06764251Liaoning Cancer Hospital & Institute20
Unknown
1 期
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)Urinary Bladder NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsAntineoplastic AgentsUrinary Bladder DiseasesTislelizumab Antineoplastic Agents, ImmunologicalNCT04922047RenJi Hospital6
Unknown
1 期
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerNon-Small Cell Lung CancerNCT05273814Tianjin Medical University Cancer Institute and Hospital30